HUTCHMED (HCM) has reported positive topline Phase III (ESLIM-02) data for its internally developed drug, sovleplenib, in warm antibody autoimmune haemolytic anaemia (wAIHA). The study met its primary endpoint, demonstrating rapid and durable haemoglobin responses in patients who had relapsed following standard treatments. Importantly, this outcome supports a planned New Drug Application (NDA) filing in China in the first half of 2026, representing a meaningful regulatory de-risking event. While ....
